SH2 and SH3 domains as targets for anti-proliferative agents

Critical Reviews in Oncology/Hematology

Volumn 40, Issue 2, 2001, Pages 175-186

  Vidal, Michel ^a   Gigoux, Véronique ^a   Garbay, Christiane ^a  

^a UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

Anticancer drug design; Antiproliferative activity; Inhibitor; Ras signaling; SH2 domain; SH3 domain

Indexed keywords

2 NAPHTHOL; ACTINOMYCIN DERIVATIVE; ADAPTOR PROTEIN; AMINO ACID; ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; CGP 78850; CGP 85793; NATURAL PRODUCT; ONCOPROTEIN; PHOSPHATASE; PHOSPHOPEPTIDE; PHOSPHOTRANSFERASE; PHOSPHOTYROSINE; PRODRUG; PROLINE DERIVATIVE; PROTEIN INHIBITOR; SYNTHETIC PEPTIDE; TRIACYLGLYCEROL LIPASE; UNCLASSIFIED DRUG;

AMINO ACID ANALYSIS; AMINO ACID SEQUENCE; ANTINEOPLASTIC ACTIVITY; CELL ACTIVITY; DRUG EFFECT; DRUG MECHANISM; GENE OVEREXPRESSION; HUMAN; NONHUMAN; PROTEIN DOMAIN; PROTEIN FOLDING; PROTEIN MOTIF; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; REVIEW; SEQUENCE HOMOLOGY; SIGNAL TRANSDUCTION; TUMOR CELL;

AMINO ACID SEQUENCE; ANIMALS; ANTINEOPLASTIC AGENTS; CELL DIVISION; DRUG DESIGN; GROWTH INHIBITORS; HYDROLYSIS; LIGANDS; MODELS, BIOLOGICAL; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; NEOPLASM PROTEINS; PHOSPHOPEPTIDES; PHOSPHORIC MONOESTER HYDROLASES; PRODRUGS; PROTEIN CONFORMATION; SIGNAL TRANSDUCTION; SRC HOMOLOGY DOMAINS; SRC-FAMILY KINASES; TUMOR STEM CELLS;

EID: 0034773599     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1040-8428(01)00142-1     Document Type: Review

References (103)

1. Inhibitors of farnesyl protein transferase: A possible cancer chemotherapeutic
2. Protein tyrosine kinase inhibitors as novel therapeutic agents
3. A noncatalytic domain conserved among cytoplasmic protein-tyrosine kinases modifies the kinase function and transforming activity of Fujinami sarcoma virus P130gag-fps
4. SH2 and SH3 domains: From structure to function
5. SH3 domains. Molecular 'Velcro'
6. SH3, an abundant protein domain in search of a function
7. SH2/SH3 signaling proteins
8. Grb2 mediates the EGF-dependent activation of guanine nucleotide exchange on Ras
9. Biochemistry of the Src protein-tyrosine kinase: Regulation by SH2 and SH3 domains
10. Src-homology 2 (SH2) domain ligation as an allosteric regulator: Modulation of phosphoinositide-specific phospholipase C gamma 1 structure and activity
11. SH2 and SH3 domains: Potential targets for anti-cancer drug design
12. SH3 domains and drug design: Ligands, structure, and biological function
13. Signal transduction drug discovery: Targets, mechanisms and structure-based design
14. Involvement of pp60c-src with two major signaling pathways in human breast cancer
15. Characterization of human epidermal growth factor receptor and c-Src interactions in human breast tumor cells
16. The SH2 and SH3 domain-containing Nck protein is oncogenic and a common target for phosphorylation by different surface receptors
17. The Nck SH2/SH3 adaptor protein: A regulator of multiple intracellular signal transduction events
18. Multiple Grb2-protein complexes in human cancer cells
19. Association of the DF3/MUCI breast cancer antigen with Grb2 and the Sos/Ras exchange protein
20. Overexpression of the Grb2 gene in human breast cancer cell lines
21. Tyrosine phosphorylation of Shc proteins and formation of Shc/Grb2 complex correlate to the transformation of NIH3T3 cells mediated by the point-mutation activated neu
22. Constitutive phosphorylation of Shc proteins in human tumors
23. Formation of Shc-Grb2 complexes is necessary to induce neoplastic transformation by overexpression of Shc proteins
24. BCR-Abl-induced oncogenesis is mediated by direct interaction with the SH2 domain of the Grb2 adaptor protein
25. Bcr-Abl oncoproteins bind directly to activators of the Ras signalling pathway
26. Tyrosine phosphorylation of murine Crkl
27. BCR-ABL-induced leukemogenesis causes phosphorylation of Hefl and its association with Crkl
28. Identification of CRKL as the constitutively phosphorylated 39-kD tyrosine phosphoprotein in chronic myelogenous leukemia cells
29. Tyrosine phosphorylation of CRKL in Philadelphia + leukemia
30. Activation of Rac1 by a Crk SH3-binding protein, DOCK180
31. Extracellular-regulated kinase activation and CAS/Crk coupling regulate cell migration and suppress apoptosis during invasion of the extracellular matrix
32. Dominant-negative mutants of Grb2 induced reversal of the transformed phenotypes caused by the point mutation-activated rat HER-2/Neu
33. Receptor-tyrosine- and G beta gamma-mediated MAP kinase activation by a common signaling pathway
34. Shc dominant negative disrupts cell cycle progression in both G0-G1 and G2-M of ErbB2-positive breast cancer cells
35. Inhibition of Grb2 and Crkl proteins results in growth inhibition of Philadelphia chromosome positive leukemic cells
36. Solution structure of the SH3 domain of Src and identification of its ligand-binding site
37. Crystal structure of a Src-homology 3 (SH3) domain
38. Solution structure and ligand-binding site of the SH3 domain of the p85 alpha subunit of phosphatidylinositol 3-kinase
39. Solution structure of the SH3 domain of phospholipase C-gamma
40. Solution structure and ligand-binding site of the carboxy-terminal SH3 domain of Grb2
41. Solution structure of GAP SH3 domain by 1H NMR and spatial arrangement of essential Ras signaling-involved sequence
42. NMR structure of the N-terminal SH3 domain of Grb2 and its complex with a proline-rich peptide from Sos
43. Two binding orientations for peptides to the Src SH3 domain: Development of a general model for SH3-ligand interactions
44. Proline-rich sequences that bind to Src homology 3 domains with individual specificities
45. Structural determinants of peptide-binding orientation and of sequence specificity in SH3 domains
46. Specific interactions outside the proline-rich core of two classes of Src homology 3 ligands
47. Biased combinatorial libraries: Novel ligands for the SH3 domain of phosphatidylinositol 3-kinase
48. Identification of a ten-amino acid proline-rich binding site
49. Cloning of ligand targets: Systematic isolation of SH3 domain-containing proteins
50. Identification of a Src SH3 domain binding motif by screening a random phage display library
51. Distinct ligand preferences of Src homology 3 domains from Src, Yes, Abl, Cortactin, p53bp2, PLCγ, Crk, and Grb2
52. Molecular basis for the binding of SH3 ligands with non-peptide elements identified by combinatorial synthesis
53. Protein structure-based combinatorial chemistry: Discovery of non-peptide binding elements to Src SH3 domain
54. Exploring the leucine-proline binding pocket of the Src SH3 domain using structure-based, split-pool synthesis and affinity-based selection
55. Exploring the specificity pockets of two homologous SH3 domains using structure-based, split-pool synthesis and affinity-based selection
56. Exploiting the basis of proline recognition by SH3 and WW domains: Design of N-substituted inhibitors
57. Design and synthesis of SH3 domain binding ligands: Modifications of the consensus sequence XPPXP
58. Identification of D-peptide ligands through mirror-image phage display
59. Crystal structure of the mammalian Grb2 adaptor
60. DNA polyintercalation: Comparison of DNA binding properties of an acridine dimer and trimer
61. A Sos-derived dimeric peptide blocks the Ras signaling pathway by binding both Grb2 SH3 domains and displays antiproliferative activity
62. Genetic engineering of proteins with cell membrane permeability
63. The third helix of the Antennapedia homeodomain translocates through biological membranes
64. Cell internalization of the third helix of the Antennapedia homeodomain is receptor-independent
65. A truncated HIV-1 Tat protein basic domain rapidly translocates through the plasma membrane and accumulates in the cell nucleus
66. Structure and function of SH2 domains
67. SH2 domain structure and function
68. Src homology-2 domains: Structure, mechanisms, and drug discovery
69. Crystal structure of the phosphotyrosine recognition domain SH2 of v-src complexed with tyrosine-phosphorylated peptides
70. Structural basis for specificity of Grb2-SH2 revealed by a novel ligand binding mode
71. Progress in the development of inhibitors of SH2 domains
72. Recent advances in the design and synthesis of SH2 inhibitors of Src, Grb2 and ZAP-70
73. Design, synthesis, and cocrystal structure of a nonpeptide Src SH2 domain ligand
74. Design of peptidomimetic ligands for the pp60src SH2 domain
75. The formation of a covalent complex between a dipeptide ligand and the Src SH2 domain
76. Structure-based design, synthesis, and X-ray crystallography of a high-affinity antagonist of the Grb2-SH2 domain containing an asparagine mimetic
77. Structure-based design and synthesis of high affinity tripeptide ligands of the Grb2-SH2 domain
78. Potent antagonists of the SH2 domain of Grb2: Optimization of the X + 1 position of 3-amino-Z-Tyr(PO3H2)-X + 1-Asn-NH2
79. Structural basis for the high affinity of amino-aromatic SH2 phosphopeptide ligands
80. Structure-based design of peptidomimetic ligands of the Grb2-SH2 domain
81. Structure-based design of a non-peptidic antagonist of the SH2 domain of Grb2
82. Small peptides containing phosphotyrosine and adjacent alphaMe-phosphotyrosine or its mimetics as highly potent inhibitors of Grb2-SH2 domain
83. Structure-based design and synthesis of phosphinate isosteres of phosphotyrosine for incorporation in Grb2-SH2 domain inhibitors. Part 1
84. Structure-based design and synthesis of phosphinate isosteres of phosphotyrosine for incorporation in Grb2-SH2 domain inhibitors. Part 2
85. Potent inhibition of Grb2-SH2 domain binding by non-phosphate-containing ligands
86. Inhibition of Grb2-SH2 domain binding by non-phosphate-containing ligands. 2. 4-(2-Malonyl)phenylalanine as a potent phosphotyrosyl mimetic
87. The role of 4-phosphonodifluoromethyl- and 4-phosphono-phenylalanine in the selectivity and cellular uptake of SH2 domain ligands
88. Selective Grb2-SH2 inhibitors as anti-Ras therapy
89. Effect of potent and selective inhibitors of the Grb2-SH2 domain on cell motility
90. Src homology-2 domains protect phosphotyrosyl residues against enzymatic dephosphorylation
91. Tyrosine-phosphorylated epidermal growth factor receptor and cellular p130 provide high affinity binding substrates to analyze Crk-phosphotyrosine-dependent interactions in vitro
92. Cyclic peptide inhibitors of phosphatidylinositol 3-kinase p85 SH2 domain binding
93. Nonphosphorylated peptide ligands for the Grb2 Src homology 2 domain
94. Cholecystokinin B antagonists strongly potentiate antinociception mediated by endogenous enkephalins
95. Inhibition of the enkephalin-metabolizing enzymes by the first systemically active mixed inhibitor prodrug RB 101 induces potent analgesic responses in mice and rats
96. Mononucleotide phosphotriester derivatives with S-acyl-2-thioethyl bioreversible phosphate-protecting groups: Intracellular delivery of 3′-azido-2′,3′-dideoxythymidine 5′-monophosphate
97. Inhibition of the ras-dependent mitogenic pathway by phosphopeptide prodrugs with antiproliferative properties
98. Actinomycin D, C2 and VII, inhibitors of Grb2-SHC interaction produced by Streptomyces
99. Covalent binding of catechols to Src family SH2 domains
100. Structure-based design of novel bicyclic nonpeptide inhibitors for the Src SH2 domain
101. Structure-based design of an osteoclast-selective, nonpeptide Src homology 2 inhibitor with in vivo antiresorptive activity
102. A Src SH2 selective binding compound inhibits osteoclast-mediated resorption
103. Src inhibitors: Drugs for the treatment of osteoporosis, cancer or both?